Control-IQ technology also offers optional settings for sleep and exercise that will change treatment values to better match the different physiologic needs during these activities. About Tandem ...

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...

The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin ...

Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference on ...

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced hybrid closed-loop algorithm. Control-IQ+, compatible ...

Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...

Tandem Diabetes Care has already proven that its closed-loop system for automated insulin delivery can improve the amount of time spent in range for people of all ages with Type 1 diabetes, but a new ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced data presented this week on real-world use of the t:slim ...